Your browser doesn't support javascript.
loading
Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review
Jonathon Senefeld; Stephen A Klassen; Shane K Ford; Chad C Wiggins; Bruce C Bostrom; Michael A Thompson; Sarah E Baker; Wayne T Nicholson; Patrick W Johnson; Rickey E Carter; Jeffrey P Henderson; William R Hartman; Liise-anne Pirofski; R. Scott Wright; DeLisa Fairweather; Katelyn A Bruno; Nigel S Paneth; Arturo Casadevall; Michael J Joyner.
Afiliação
  • Jonathon Senefeld; Mayo Clinic
  • Stephen A Klassen; Mayo Clinic
  • Shane K Ford; Mayo Clinic
  • Chad C Wiggins; Mayo Clinic
  • Bruce C Bostrom; Children's Hospital of Minnesota
  • Michael A Thompson; Aurora Cancer Care, Advocate Aurora Health
  • Sarah E Baker; Mayo Clinic
  • Wayne T Nicholson; Mayo Clinic
  • Patrick W Johnson; Mayo Clinic
  • Rickey E Carter; Mayo Clinic
  • Jeffrey P Henderson; Washington University School of Medicine in St. Louis
  • William R Hartman; University of Wisconsin-Madison
  • Liise-anne Pirofski; Albert Einstein College of Medicine
  • R. Scott Wright; Mayo Clinic
  • DeLisa Fairweather; Mayo Clinic
  • Katelyn A Bruno; Mayo Clinic
  • Nigel S Paneth; Michigan State University
  • Arturo Casadevall; Johns Hopkins School of Public Health
  • Michael J Joyner; Mayo Clinic
Preprint em Inglês | medRxiv | ID: ppmedrxiv-20224790
ABSTRACT
0In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico / Review / Revisão sistemática Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico / Review / Revisão sistemática Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...